We systematically reviewed the peer-reviewed literature to relate the survival of hybrid metal-on-metal hip resurfacing arthroplasty devices to a National Institute of Clinical Excellence (NICE) benchmark for choosing a primary total hip replacement, which is a survival rate of 90% at a follow-up of ten years.
We systematically reviewed the peer-reviewed literature to relate the survival of hybrid metal-on-metal hip resurfacing arthroplasty devices to a National Institute of Clinical Excellence (NICE) benchmark for choosing a primary total hip replacement, which is a survival rate of 90% at a follow-up of ten years.
A total of 29 articles (10 621 resurfaced hips) met the inclusion criteria. The mean followup ranged from 0.6 to 10.5 years and the survival of the implant ranged from 84% to 100%. Of the 10 621 hips, 370 were revised (3.5%), with aseptic loosening as the most frequent mode of failure.
None of the hip resurfacing arthroplasty implants used to date met the full ten-year NICE benchmark of survival. A total of 13 studies showed satisfactory survival compared with the three-year NICE benchmark.
Hip resurfacing arthroplasty (HRA) has regained popularity since the introduction of the third generation of implants in the mid-1980s. Both the first-(metal-on-polyethylene) and the second-generation (cementless metal-on-metal) resurfacings failed because of high rates of wear and aseptic loosening. 1 The current thirdgeneration hip resurfacing implants consist of a cemented femoral component and a press-fit acetabular component. 1 Some surgeons are hesitant to use HRA because of the failure rates of the first-and second-generation implants 2, 3 and the complications, which include fracture of the femoral neck, metal hypersensitivity and increased serum levels of metal ions. [4] [5] [6] [7] Those in favour of the technique indicate the possible advantages of conserved femoral bone stock, minimal wear and a reduced risk of dislocation due to the large diameter of the components. [8] [9] [10] [11] [12] These advantages would suit the lifestyle of younger patients. 13, 14 With HRA promoted for use in young active patients, its use may not be entirely comparable with total hip replacement (THR). 15 There remains a continuing debate on the possible advantages of HRA. 16 The National Institute for Health and Clinical Excellence (NICE), as part of the National Health Service (NHS) for England and Wales, has indicated that a revision rate of 10% or less at ten years should be regarded as the current benchmark of the satisfactory performance of a primary THR. This applies to all forms of replacement including both conventional and resurfacing implants. 17 Prostheses unable to satisfy these requirements should be appropriately investigated. In its appraisal of THRs, implants may also be recommended if their reported implant revision rate at a follow-up of at least three years is consistent with this tenyear benchmark. 17 Although several reviews on HRA have been published recently, no studies have compared the survival of the HRA implant with an objective benchmark. 18, 19 In our systematic review, we hypothesised that primary hybrid metalon-metal HRA is compliant with the NICE benchmark of a revision rate of 10% or less at a follow-up of ten years.
Materials and Methods
The Cochrane Library, EMBASE and MED-LINE electronic bibliographic databases were searched by an independent librarian. The search was conducted using standard software (Pubmed 2009 database for searching MED-LINE, OVID software (OvidSP_U102. 03.00.130; Ovid Technologies, Sandy, Utah) for searching EMBASE). The electronic search included articles published until June 2010. In combination with the booleans 'AND', 'NOT' and 'OR' the following search terms were used, with asterisks indicating where truncated search terms were used to yield the widest ranges of results: hip, femur head, femoral head, femur neck, femoral neck, resurfac treatment failure, re-operation, longevity, success, recovery of function, range of motion, joint instability, osteonecrosis, osteoarthritis, pseudotumor, pseudotumour, mechanical stress, gait, patient satisfaction, activity, activities, surviv * and risk factors. Reference lists in the included studies were hand searched for other relevant studies. Although only peer-reviewed publications were considered for inclusion, we tried to include all available studies by asking all implant manufacturers if they were aware of any (un-)published data. Also, experts in this field were contacted to determine if there were unpublished data.
All the titles and abstracts were examined to assess their relevance. Only studies meeting the following eligibility criteria were included: any systematic review, clinical trial or case series using a metal-on-metal resurfacing prosthesis with a cemented femoral component and an uncemented acetabular component implanted after 1988; reports of the survival of the implant defined as time to revision; a minimum requirement of 75 HRA procedures to ensure that the learning curve was completed;
20-26 basic clinical details including age, gender and aetiology; validated patient reported outcomes of pain, stiffness, functional impairment and quality of life such as the Harris hip score (HHS), 27 the Oxford hip score, 28 the University of California, Los Angeles (UCLA) hip rating system, 29 the score of Merle d'Aubigné and Postel; 30 and the mechanisms of failure such as fracture of the femoral neck and aseptic loosening.
No language restrictions were applied. A native speaker was consulted for articles published in languages other than English. Case reports and articles published before 1988 were excluded, since current implants on the market had been introduced after 1988. 1 The inclusion and exclusion criteria were checked in all identified abstracts by two independent reviewers (WvdW, TS). In case of disagreement, a third reviewer was consulted. The full texts were retrieved and further checked for inclusion and exclusion criteria. If articles described the same series of patients, only the most recent with the largest number of patients was included. Articles with usable information (n = 29) Fig. 1 Diagram showing the study flow (MoM, metal-on-metal; HRA, hip resurfacing arthroplasty).
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Extraction of data focused on the baseline clinical details and aetiology, the types of implant used, details of followup, standardised clinical scores, radiological findings, implant survival rates, complications not requiring revision and the modes of failure.
Data extraction was undertaken by one author (WvdW) and validated by a second (TS). A third was consulted if there was disagreement. All the extracted data were summarised and pooled whenever possible. The survival rate of the implants was plotted against the follow-up mean for comparison with the NICE benchmark. The quality of the evidence was judged using the Grading of Recommendations Assessment, Development and Evaluations (GRADE) recommendations, resulting in the grading of quality as high, moderate, low or very low. 31 In order to compare different clinical scores, we normalised the scores to a new score whenever possible, ranging from 0 to 100, with 100 being the best possible score.
Results
We identified 539 abstracts. Data were extracted from 29 papers. A flow chart, compliant with the Quality of Reporting of Meta-Analysis statement, detailing the study selection, is presented in Figure 1 . 55 Data were thus presented on five of 11 resurfacing devices on the market. We could not identify studies which met our inclusion criteria describing the use of the Accis (Implantcast GmbH, Buxtehude, Germany), Adept (Finsbury Orthopaedics), EskaBionik (Eska Implants, Lubeck, Germany), Icon (International Orthopaedics, Geisingen, Germany), Mitch (Stryker, Kalamazoo, Michigan) or Recap (Biomet Inc., Warsaw, Indiana) resurfacing devices.
The studies included one randomised, clinical trial, 27 prospective case series and one retrospective case series. [9] [10] [11] [22] [23] [24] [25] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] The mean follow-up ranged from 0.6 to 10.5 years. The highest reported loss to follow-up was 8.3% 50 and 11 studies reported no loss to follow-up. 11, 22, 25, 34, 35, 42, 48, 49, [52] [53] [54] The survival of the implant ranged between 84% and 100% ( Fig. 2 ). In 13 of 17 studies with a follow-up of between three and 11 years, the survival rate was compliant with the NICE benchmark. [9] [10] [11] 35, [37] [38] [39] 43, 44, 46, 47, 49, 54 These 13 studies used either the BHR implant (eight), the Conserve Plus (two), the Durom (one), the Cormet 2000 (one) or both the McMinn and the BHR implants (one). The four studies not compliant with this benchmark, but with follow-up of more than three years, used either the ASR device (two), the BHR (one) or the second-generation McMinn device 11, 33, 34, 40 (Fig. 2) . The only randomised, controlled trial reported a lower survival rate for the HRA group compared with the THR group, 96.3% versus 98% at 5.6 years. 54 The mean follow-up was less than three years in 12 studies. 22, 24, 25, 36, 41, 42, 45, 48, [50] [51] [52] [53] Details on the number of hips per study, the clinical details, the duration of follow-up, the loss to follow-up and implant survival are presented in Table I .
Careful patient selection based on gender, age and the preoperative diagnosis is important for HRA. 34, 56 In two of the 29 studies which were included, most of the patients were female, reporting a survival rate of 88.7% at one year and of 94.2% at a mean of 2.8 years. 22, 24 With these results, neither study was compliant with the NICE benchmark.
The mean age of the patients in the included studies ranged from 42 to 58 years. In six studies the mean age was more than 55 years, and three of these studies had an implant survival rate higher than that required by the three-year entry NICE benchmark. 22, 25, 34, 42, 44, 49 In three studies, all the included patients had a preoperative diagnosis of primary osteoarthritis. 11, 22, 43 Two were compliant with the NICE benchmark. 11, 43 In two less than 50% of patients had primary osteoarthritis as the pre-operative diagnosis. One was compliant with the NICE benchmark, the other was not. 45, 54 Four studies presented details on the surgeon's learning curve. All reported that there were fewer cases of revision at the end of the series compared with the beginning. Graph showing the survival of the implants against time.
According to the GRADE recommendations, the quality of the evidence was very low. The clinical outcome was presented in a very heterogeneous manner, using six different scoring systems, some in modified form. Most frequently used (22 studies) was the HHS and in those studies, the mean score improved by 40.8 points (95% confidence failure with metallosis and soft-tissue necrosis. This response was possibly due to an acquired sensitivity to metal ions, leading to aseptic lymphocytic-vasculitisassociated lesions (ALVAL). At follow-up at five years the rate of revision which was related to the metallosis was 3.1%. The reported risk factors for metallosis were female gender, a small femoral component, a high abduction angle and obesity. Three other studies reported a marked inflammatory response when performing a revision procedure for pain. 10, 43, 48 The 29 studies represented a total of 10 621 HRA procedures. A total of 370 were revised (3.5%). The reported reasons for failure were aseptic loosening (1.4%), fracture of the femoral neck (1.1%), infection (0.2%), avascular necrosis of the femoral head (0.2%), ALVAL (0.13%), persistent pain (0.1%), dislocation (0.08%), malpositioning of a component (0.08%) or other unspecified reasons (0.2%). The study by Daniel et al 55 using a specific series of double-heat-treated resurfacing devices, which are no longer in use, can be regarded as an outlier. In this series, 16% of hips were revised for aseptic loosening. In all other studies, this percentage was less than 6% (Table IV) .
Clinical complications and adverse events without the need for revision were reported in 25 of the 29 studies. In these 25 studies (9446 patients), 529 complications were reported (5.6%). Steffen et al 10 reported no major complications without providing further details. In their series of 337 HRAs, Stulberg et al 50 reported hip-related complications in 83 (24.6%) and implant-related complications in 32 (9.5%), without further details. Beaulé et al 47 reported re-operation on 28 patients (24.1%) because of loosening of the internal fixation in seven and complete removal of the fixation because of bursitis in 21. Both reasons for reoperation were specifically associated with the Ganz approach used in this series.
Based on the remaining studies involving HRAs (8338) in which the complications were reported in detail, the most frequent was painless clicking of the hip (1.2%) followed by a nerve palsy (0.8%), deep-vein thrombosis (0.6%), dislocation (0.3%), squeaking (0.2%), wound infection (0.1%) and pulmonary embolism (0.1%). 9, 11, 22, 24, 25, 33, 34, [36] [37] [38] [39] [40] [41] [42] [43] 45, 46, 48, 49, [51] [52] [53] [54] [55] Heilpern et al 37 and Witzleb et al 45 each reported one patient with an undisplaced fracture of the the femoral neck which healed with conservative treatment.
Discussion
All but one of the implants studied had insufficient followup to be compliant with the NICE benchmark, of a revision rate of less than 10% at ten years, for choosing a prosthesis for primary THR. The study reporting a follow-up of longer than ten years had a revision rate of 16%, mainly for aseptic loosening of the implant. This high failure rate was attributed to the double-heat-treatment manufacturing process which is no longer in use. 55 The prosthesis was superseded by the Cormet 2000 implant in 1996.
Compared with the three-year NICE entry-benchmark of implant survival ≥ 97%, 13 studies (44.8%) showed satisfactory survival. Eight used the BHR implant, two the Conserve plus, one the Durom, one the Cormet 2000 and one both the McMinn and BHR implants. [9] [10] [11] 35, [37] [38] [39] 43, 44, 46, 47, 54 There appeared to be a difference in the performance of the implants, with only the ASR appearing below the benchmark in four studies, in two of which the follow-up was very short. The BHR appeared above the line in 12 of 13 studies. Both the Conserve plus (four studies) and the Cormet implant (two studies) had an equal number above and below the line. The Durom implant had three studies above and one below the line. Since we excluded studies with incomplete learning curves, these results are more likely to be attributed to the characteristics of the implant such as the design and manufacturing process (Fig. 2) .
No survival data were analysed for six of 11 HRA devices on the market (Accis, Adept, Eska, Icon, Mitch and Recap). However, the implants in the studies which were included represented most of the HRA implants worldwide.
57-59
Aseptic loosening was the most frequent cause of failure (1.4%), followed by fracture of the femoral neck (1.1%). The variation in frequency of fracture of the femoral neck among studies was large, between 0% and 16.3% compared with the frequency of aseptic loosening (0.0% to 5.5%). Clinical outcome scores were reported very heterogeneously, but all studies showed a significant improvement from the pre-operative score.
In all of the included studies on HRA the patients were relatively young with the mean age ranging between 42 and 58 years. This is important when comparing the failure rates of HRA with those of conventional THR, since most patients within this age range will be considerably more active than those aged more than 60 years. National Joint Registries are useful for this comparison since they combine different types of conventional THR and publish their data stratified by age.
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Our pooled revision rate of 3.5% is higher than the revision rates at three years for conventional THRs in patients aged under 55 years reported in the sixth annual report from the National Joint Registry for England and Wales, 57 but lower than that for HRA of 4.5% (95% CI 3.9 to 5.3). 57 Both the cumulative revision rate at eight years for THR and for HRA in patients aged less than 55 years in The Australian National Joint Replacement Registry Report (4% and 4.7%, respectively) are higher than our pooled revision rate. 61 As with the results for HRA presented in our review, there is much variation in reported survival rates for THR, ranging from less than 80% to 99% at ten years for patients aged less than 55 years. 24, 58 However, the pattern of the modes of failure is different. For HRA, fracture of the femoral neck is a unique mode of failure, but according to our results aseptic loosening occurs slightly more frequently, 1.1% versus 1.4% respectively.
According to the Finnish Arthroplasty Registry, in patients under 55 years of age with primary osteoarthritis, the survival rate at ten years of less than 80% for THR is mainly due to wear of the liner. This required only its exchange at revision surgery. 62 Excessive wear in HRA leads to increased levels of metal ions in the blood with ALVAL as a possible serious consequence. This is not unique to HRA. In a randomised trial, Garbuz et al 63 reported a 46-fold increase in metal ion concentrations in the blood in patients with large-diameter metal-on-metal THRs, compared with a tenfold increase in patients who had undergone HRA. 63 Failure due to dislocation, a common cause of revision of THR, is rare in HRA. In our review, only 27 of 10 621 HRAs were revised for dislocation (0.3%). Arguably, the same low rate of dislocation could be achieved using a large-headed THR, but without the perceived benefit of retained femoral bone stock. However, the use of bearings of large diameter appears to be effective against the risk of dislocation.
In 2002 two systematic reviews of the literature up to 2001 were published, both presenting the results of one literature search. 64, 65 Based on the publication date, our systematic review included 29 new studies. Compared with several recent reviews on HRA, our study was designed as a systematic review focusing on survival of the implant compared with the NICE benchmark. 18, 19 The strengths of our review included a comprehensive and reproducible search strategy, exclusion of duplicate case series and studies with an incomplete learning curve, contact with authors for clarification, a comparison with an objective revision rate benchmark and the use of the GRADE system for assessment of quality. Finally, survival of the implant defined as years to revision surgery was an objective and patient-relevant endpoint. Our study is limited since 28 of the 29 were case series, possibly introducing bias. A requirement of a minimum of 75 treated patients resulted in the exclusion of studies describing metal-ion release. These are expensive to perform and accordingly restrict the number of patients studied. The few which included this information and had more than 75 patients were excluded since they did not present data on survival of the implant. The quality of the included studies was very low according to the GRADE system, which is mainly based on the design of the study and heterogeneous reporting of clinical scores and radiological findings.
Based on our findings there remain concerns on the longterm effectiveness and safety and longer follow-up is needed. The large variation in the incidence of fracture of the femoral neck as a mode of failure in studies is poorly understood. However, the most frequent mode of failure after HRA remains aseptic loosening.
